We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aoti Inc. | LSE:AOTI | London | Ordinary Share | COM SHS USD0.00001 (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 90.00 | 10,000 | 08:00:10 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 85.00 | 95.00 | 90.00 | 87.50 | 90.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Spec Outpatient Facility,nec | USD 58.36M | USD -1.76M | USD - | - | 95.72M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 07:25:38 | O | 5,000 | 90.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/6/2025 | 07:00 | UK RNS | AOTI, Inc. End of Distribution Compliance Period |
| 27/5/2025 | 07:00 | UK RNS | AOTI, Inc. 2024 Annual Report and Notice of AGM |
| 19/5/2025 | 07:00 | UK RNS | AOTI, Inc. Presentation at AJ Bell and Shares Spotlight Event |
| 13/5/2025 | 07:00 | UK RNS | AOTI, Inc. Director Shareholding - Share Purchase |
| 07/5/2025 | 07:00 | UK RNS | AOTI, Inc. Director Shareholding - Share Purchase |
| 02/5/2025 | 11:14 | UK RNS | AOTI, Inc. Director/PDMR Shareholding |
| 28/4/2025 | 12:26 | ALNC |  AOTI loss narrows in 2024 amid growth across all segments |
| 28/4/2025 | 07:30 | ALNC | *AOTI expects 2025 adj Ebitda margin to be 14-16% |
| 28/4/2025 | 07:00 | UK RNS | AOTI, Inc. 2024 Final Results |
| 23/4/2025 | 07:00 | UK RNS | AOTI, Inc. Investor Presentation via Investor Meet Company |
Aoti (AOTI) Share Charts1 Year Aoti Chart |
|
1 Month Aoti Chart |
Intraday Aoti Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 22/6/2025 09:20 by Aoti Daily Update Aoti Inc. is listed in the Spec Outpatient Facility,nec sector of the London Stock Exchange with ticker AOTI. The last closing price for Aoti was 90p.Aoti currently has 106,359,241 shares in issue. The market capitalisation of Aoti is -. This morning AOTI shares opened at 90p |
Posted at 19/5/2025 09:28 by robsy2 The CFO and others have bought stock and they seem to be trying to get the word out re AJ Bell and Investor Meet. This should firm the price up a bit. |
Posted at 28/4/2025 08:30 by robsy2 Results read ok but with some words of caution.The post IPO drop looks unjustified as they seem to be delivering.The fact you can't buy the stock on HL platform is probably not helping, HL says the following Aoti Inc (AOTI) is subject to Reg S Cat 3 restrictions, therefore we are only allow sales on this stock and further buys are restricted as it does not adhere to our platform requirements. I gather that Peel Hunt are trying to get these restrictions lifted, but no sign of that having happened as of today. Apparently the shares are tradeable on AJ Bell. |
Posted at 22/4/2025 09:35 by melody9999 This all looks rather good to me:TWO2® therapy to be included in NHS supply chain framework agreement for 2025 Peer-reviewed health economic study shows TWO2® therapy would significantly lower overall diabetic foot care costs for NHS in England AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, announces its multi-modality Topical Wound Oxygen (TWO2®) therapy has been awarded inclusion by NHS Supply Chain to the framework agreement for Advanced Wound Care 2025, which becomes effective on 1st September 2025. This follows the recent publication of the results from a new health economic (HE) study in the Journal of Diabetic Complications1 and authored by a team of leading UK-based health economists and diabetic foot clinical experts, demonstrating that adoption of AOTI's unique TWO2® therapy within the National Health Service (NHS) in England, UK, would significantly lower overall diabetic foot care costs. In England, the estimated cost of diabetic foot disease is almost 1% of the entire annual NHS budget, which is forecast to reach £192 billion in 2025,2,3 with non-healing ulcers being the major cost driver. Up to one third of diabetics will suffer from a diabetic foot ulcer (DFU) in their lifetime, which are the leading cause of morbidity and lower extremity amputations in the diabetic population. It is estimated that approximately 66% of DFUs do not heal within a year, and approximately 50% become infected, which can lead to life-threatening infections, hospitalisations and limb amputation. Dr. Mike Griffiths, Chief Executive Officer & President of AOTI, commented: "It is exciting to see acknowledgement of the clinical and health economic benefits delivered by our unique cyclical-pressure TWO2® therapy with its inclusion in the new framework agreement for Advanced Wound Care. Once implemented patients across England will have easier access to our proven limb saving outcomes and the NHS can start to realise substantial cost savings. These benefits are driven by significantly reduced wound recurrence, hospitalisations and amputations, all of which translate to improved quality of life for patients living with these non-healing foot ulcers." NHS supply chain framework agreements, which can run for a period of up to 48 months, enable NHS trusts and healthcare organisations to procure goods and services. They provide a single route to market for suppliers, simplify procurement, and aim to deliver cost savings and efficiency while maintaining high clinical standards. HE study supports cost savings and improved outcomes from NHS adoption of TWO2 Therapy The authors of the study developed a comprehensive health economic model to estimate the cost effectiveness of TWO2® therapy, using both the durable healing outcomes demonstrated in the pivotal TWO2 Randomised Control Trial (RCT) and UK healthcare cost norms. The model predicts that TWO2® therapy would increase Quality Adjusted Life Years (QALYs) and significantly improve outcomes relative to standard care, while lowering costs by an estimated £5,038 per patient, or 16%, over the course of two years compared to the standard care cost of £31,275 per patient over the same period, meeting the QALY threshold commonly used by the National Institute for Health and Care Excellence (NICE) to determine whether new technology is considered "good value for money" and therefore suitable for funding within the NHS.5 AOTI has submitted its needs assessment application through NHS Innovation Service and looks forward to a future NICE technology appraisal (TA) guidance. |
Posted at 06/12/2024 23:14 by rambutan2 AOTI is a medical technology group with a mission to help all people with chronic conditions get back to living their lives to the fullest. Based in Oceanside, California, the Group is focused on the durable healing of wounds and prevention of amputations that are caused by various chronic wound conditions. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
